RxDoctor Payments Data

Victoria Gordon, MD

Family Medicine · Orange, TXNPI 1972514461

Payments from drug & device makers

$10,052in general payments, 2019–2025

Across 635 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$912
  • Novo Nordisk$894
  • GSK$753
  • Lilly USA, LLC$610
  • Astellas Pharma US Inc$559
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,035100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,052 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$77,794
Medicare patients
213
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide109$157,504
Trelegy ElliptaFluticasone/Umeclidin/Vilanter147$139,833
OzempicSemaglutide93$118,348
EliquisApixaban98$98,935
FarxigaDapagliflozin Propanediol93$95,326
MyrbetriqMirabegron63$55,378
XareltoRivaroxaban60$53,999
Amlodipine-ValsartanAmlodipine Besylate/Valsartan303$44,925
JardianceEmpagliflozin38$42,173
JanuviaSitagliptin Phosphate29$39,318
Tresiba Flextouch U-200Insulin Degludec36$27,782
MounjaroTirzepatide17$22,720
TrulicityDulaglutide11$21,419
Tresiba Flextouch U-100Insulin Degludec37$19,518
Breo ElliptaFluticasone/Vilanterol35$16,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$894$275,852202 claims
GSKTrelegy Ellipta, Breo Ellipta$753$156,791182 claims
AstraZenecaFarxiga, Breztri Aerosphere$912$109,876116 claims
PfizerEliquis$485$98,93598 claims
Astellas Pharma US IncMyrbetriq$559$55,37863 claims
Johnson & JohnsonXarelto$318$53,99960 claims
MerckJanuvia, Janumet Xr$341$45,95444 claims
Lilly USA, LLCMounjaro, Trulicity$610$44,13928 claims
Boehringer IngelheimJardiance$323$42,17338 claims
AbbVieVraylar$2,111$16,39311 claims
Sumitomo Pharma America, Inc.Gemtesa$90$11,03412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Orange

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →